mani
biomark
discov
proteom
analysi
fewer
develop
clinic
use
report
biomark
involv
posttransl
modif
degrad
unclear
level
biomark
chang
diseas
thu
need
establish
link
synthet
mechan
biomark
diseas
condit
practic
use
clinic
diagnosi
fibrinogen
alpha
c
chain
kda
fragment
new
serum
marker
chronic
hepat
discov
sampl
alcohol
liver
diseas
use
selditof
ms
deriv
ctermin
region
fibrinogen
alpha
chain
molecular
weight
da
fig
establish
level
high
healthi
peopl
low
onset
hepat
develop
elisa
system
evalu
clinic
util
variou
kind
chronic
hepat
result
show
serum
level
significantli
decreas
earli
stage
liver
fibrosi
show
strong
indic
liver
fibrosi
also
found
natur
releas
fibrinogen
neglig
blood
circul
healthi
subject
clearli
detect
serum
collect
tube
thu
conclud
releas
fibrinogen
process
blood
coagul
vitro
product
releas
blood
clot
fibrinogen
fig
sinc
initi
identif
peptid
identifi
complet
complet
mass
report
biomark
sever
patholog
condit
includ
cancer
inflammatori
disord
howev
mechan
releas
fibrinogen
unknown
base
studi
formul
hypothesi
releas
fibrinogen
fibrin
enzym
activ
postblood
collect
especi
focus
coagul
fibrinolysi
factor
sequenc
includ
amino
acid
fibrinogen
alpha
chain
fig
appear
synthes
cleavag
rgksss
ntermin
region
rpvrgi
ctermin
region
coagul
fibrinolysi
factor
thrombin
plasmin
major
enzym
cleav
carboxyl
side
lysin
work
fibrinogen
fibrin
fewer
report
enzym
blood
cleav
carboxyl
side
valin
neutrophil
elastas
one
exampl
studi
first
step
toward
understand
mechan
chang
variou
patholog
test
hypothesi
releas
enzym
appar
healthi
subject
confirm
conclus
previou
studi
regard
role
coagul
factor
synthesi
coagul
cascad
reactiv
ad
thrombocheck
apttsla
sysmex
corp
hyogo
japan
coagulationdefici
plasma
factor
ii
v
vii
viii
ix
x
xi
xii
sysmex
control
plasma
collect
insepack
ii
sodium
citrat
type
sekisui
medic
co
tokyo
japan
incub
sampl
centrifug
min
supernat
purifi
cartridg
level
sampl
measur
malditof
ms
bruker
mass
spectromet
use
stabl
isotopelabel
intern
standard
experi
done
triplic
purifi
fibrinogen
wako
pure
chemic
industri
tokyo
japan
pb
buffer
incub
thrombin
wako
final
conc
uml
plasmin
wako
uml
neutrophil
elastas
sigmaaldrich
st
loui
mo
usa
uml
h
reaction
stop
ad
edta
ph
mm
aprotinin
wako
uml
condit
purifi
fibrinogen
extens
degrad
thrombin
plasmin
neutrophil
elastas
stagetip
thermo
fisher
scientif
waltham
usa
use
desalt
degrad
product
fibrinogen
obtain
peptid
identifi
lcmsm
analysi
serum
collect
tube
tube
evacu
insepack
ii
sekisui
medic
co
ad
thrombin
wako
uml
hirudin
thermo
fisher
uml
plasmin
wako
uml
tranexam
acid
wako
mm
sivelestat
sodium
cosmo
bio
co
tokyo
japan
volum
salin
use
collect
blood
sampl
eleven
healthi
volunt
evacu
blood
collect
system
nipro
co
osaka
japan
collect
blood
clot
min
blood
clot
serum
obtain
centrifug
min
level
measur
use
elisa
kit
describ
written
inform
consent
obtain
prior
sampl
collect
studi
approv
research
ethic
committe
graduat
school
medicin
chiba
univers
approv
statist
analysi
perform
utest
spss
softwar
version
spss
inc
chicago
il
usa
p
valu
consid
signific
reconfirm
releas
fibrinogen
serum
collect
tube
blood
clot
studi
releas
analysi
use
coagulationdefici
plasma
defici
factor
ii
v
viii
x
decreas
releas
fibrinogen
addit
file
factor
ii
thrombin
particularli
mark
effect
releas
fibrinogen
reconfirm
releas
serum
collect
tube
blood
clot
determin
coagul
fibrinolysi
factor
respons
releas
narrow
candid
enzym
base
result
inform
enzym
cleavag
site
obtain
peptidas
databas
merop
http
meropssangeracuk
access
septemb
final
choos
thrombin
plasmin
neutrophil
elastas
degrad
purifi
fibrinogen
enzym
sequenc
degrad
product
analyz
fig
addit
file
degrad
condit
show
sever
cleavag
site
found
fibrinogen
alpha
c
termin
domain
especi
ntermin
region
rgksss
cleav
thrombin
plasmin
ctermin
region
rpvrgi
cleav
neutrophil
elastas
tri
fibrinogen
digest
experi
use
thrombin
plasmin
neutrophil
elastas
mixtur
could
form
fibrinogen
observ
fragment
vitro
data
shown
determin
thrombin
plasmin
neutrophil
elastas
releas
fibrinogen
blood
analyz
time
cours
releas
evacu
blood
collect
system
firstli
examin
time
cours
releas
plain
silicaco
tube
measur
level
serum
min
clot
rate
releas
silicaco
tube
significantli
faster
plain
tube
addit
file
final
level
differ
significantli
analys
perform
silicaco
tube
next
examin
time
cours
releas
contain
thrombin
hirudin
thrombin
inhibitor
plasmin
tranexam
acid
plasmin
inhibitor
sivelestat
sodium
neutrophil
elastas
inhibitor
fig
experi
fig
min
clot
could
elimin
time
lag
serum
separ
time
blood
reach
venou
blood
collect
needl
blood
collect
tube
centrifug
durat
level
found
zero
min
rate
releas
fibrinogen
ad
thrombin
significantli
faster
silicaco
tube
releas
ad
thrombin
reach
plateau
min
clot
amount
silicaco
plain
tube
fig
addit
hirudin
thrombin
inhibitor
significantli
delay
releas
prolong
min
clot
addit
plasmin
significantli
increas
releas
rate
total
amount
addit
tranexam
acid
plasmin
inhibitor
markedli
decreas
releas
fig
addit
sivelestat
sodium
neutrophil
elastas
inhibitor
strongli
inhibit
releas
fig
studi
formul
hypothesi
releas
fibrinogen
coagul
fibrinolysi
factor
firstli
analyz
vitro
releas
fragment
fibrinogen
digest
thrombin
plasmin
neutrophil
elastas
use
fig
success
analyz
time
cours
releas
determin
serum
collect
tube
spike
thrombin
inhibitor
hirudin
plasmin
inhibitor
tranexam
acid
sivelestat
sodium
neutrophil
elastas
inhibitor
fig
conclud
analysi
show
thrombin
act
initi
releas
mainli
plasmin
cleav
ntermin
end
neutrophil
elastas
cleav
ctermin
end
fibrinogen
analysi
show
ntermin
end
rgksss
cleav
thrombin
plasmin
ctermin
end
rpvrgi
cleav
neutrophil
elastas
fig
confirm
enzym
releas
blood
coagul
analyz
time
cours
releas
determin
serum
collect
tube
spike
thrombin
inhibitor
hirudin
plasmin
inhibitor
tranexam
acid
sivelestat
sodium
neutrophil
elastas
inhibitor
fig
addit
thrombin
inhibitor
hirudin
acceler
delay
releas
fibrinogen
amount
min
clot
signific
clear
blood
clot
initi
releas
neglig
blood
circul
found
serum
collect
tube
howev
result
demonstr
thrombin
play
main
role
releas
blood
clot
process
start
serum
collect
tube
conclud
thrombin
play
role
initi
element
releas
start
blood
clot
activ
hand
addit
plasmin
suffici
acceler
releas
increas
substanti
amount
think
thrombin
initi
element
releas
result
indic
plasmin
major
enzym
cleav
ntermin
region
affect
amount
natur
activ
plasminogen
plasmin
occur
activ
coagul
factor
includ
thrombin
report
also
support
role
thrombin
initi
synthesi
inhibit
plasmin
activ
significantli
suppress
releas
fibrinogen
fig
suppress
plasmin
tranexam
acid
signific
complet
may
due
enzym
cleav
ntermin
end
fact
vitro
digest
experi
fig
show
thrombin
cleav
ntermin
end
taken
togeth
plasmin
seem
play
main
role
cleav
ntermin
end
releas
discuss
enzym
cleav
ntermin
end
result
also
indic
neutrophil
elastas
play
import
role
cleav
ctermin
end
fig
result
vitro
digest
experi
fig
show
ctermin
end
rpvrgi
cleav
neutrophil
elastas
inhibit
activ
strongli
suppress
releas
serum
collect
tube
fig
suppress
neutrophil
elastas
complet
inhibit
releas
fibrinogen
fig
impli
neutrophil
elastas
play
major
role
cleav
ctermin
end
releas
fibrinogen
experi
serum
collect
tube
detect
min
clot
inhibitor
ad
tube
fig
estim
phenomenon
caus
blood
collect
process
moment
blood
reach
serum
collect
tube
blood
pass
blood
collect
needl
thin
tube
connect
needl
serum
collect
tube
clearli
blood
coagul
process
alreadi
start
blood
reach
serum
collect
tube
centrifug
durat
min
result
show
mechan
releas
healthi
peopl
strongli
relat
coagul
fibrinolysi
factor
result
suggest
marker
alcohol
liver
diseas
liver
fibrosi
neutrophil
elastas
cleav
ctermin
site
report
indic
level
neutrophil
elastas
neutrophil
count
chang
earli
stage
chronic
hepat
therefor
ctermin
site
like
cleav
similar
level
healthi
peopl
patient
chronic
hepat
howev
extrem
increas
decreas
neutrophil
might
affect
releas
spike
test
neutrophil
elastas
collect
tube
could
perform
could
obtain
enough
amount
elastas
inde
signific
volum
enzym
need
experi
blood
collect
tube
howev
result
indic
neutrophil
elastas
cleav
ctermin
region
requir
confirm
studi
thrombin
seem
initi
synthesi
plasmin
significantli
cleav
ntermin
site
molecular
marker
liver
diseas
partli
enzym
secret
liver
presenc
factor
relat
releas
also
consid
recent
marfa
et
al
report
reduc
express
level
fibrinogen
alpha
chain
mrna
note
level
relat
liver
fibrosi
hepat
addit
plasma
fibrinogen
propos
marker
chronic
liver
diseas
report
show
low
level
releas
chronic
hepat
simpli
due
enzymat
reaction
also
decreas
fibrinogen
synthesi
decreas
precursor
thu
seem
sever
factor
involv
determin
level
measur
degrad
product
blood
circul
commonli
use
clinic
test
coagul
fibrinolysi
factor
unstabl
measur
activ
exemplifi
activ
partial
thromboplastin
time
aptt
prothrombin
time
pt
also
degrad
product
fibrinogen
alpha
chain
releas
coagul
fibrinolysi
factor
reflect
minut
chang
factor
thrombin
plasmin
neutrophil
elastas
involv
key
mechan
releas
clot
normal
blood
provid
basi
understand
decreas
clot
blood
patient
chronic
hepat
analysi
may
show
similar
effect
blood
patient
sever
diseas
